Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant

We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Abhyankar, Mayuresh M., Mann, Barbara J., Sturek, Jeffrey M., Brovero, Savannah, Moreau, G. Brett, Sengar, Anjali, Richardson, Crystal M., Agah, Sayeh, Pomés, Anna, Kasson, Peter M., Tomai, Mark A., Fox, Christopher B., Petri, William A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602664/
https://www.ncbi.nlm.nih.gov/pubmed/34795290
http://dx.doi.org/10.1038/s41541-021-00399-0
Descripción
Sumario:We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lungs upon challenge. The adjuvanted vaccine also elicited systemic and local anti-Spike IgA which can be an important feature for a COVID-19 vaccine.

Ejemplares similares